Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8386 to 8400 of 8942 results

  1. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

  2. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

  3. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

  4. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163

  5. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

  6. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

  7. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

  8. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

  9. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

  10. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

  11. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

  12. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

  13. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

  14. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

  15. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC